X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration grants Elanco Animal Health an exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. Under the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal antibody products.
Lead Product(s): KIND-030
Therapeutic Area: Infections and Infectious Diseases Product Name: KIND-030
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: KindredBio
Deal Size: $16.5 million Upfront Cash: $0.5 million
Deal Type: Collaboration December 11, 2020
Details:
Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.
Lead Product(s): Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $55.0 million Upfront Cash: $55.0 million
Deal Type: Agreement February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
